CD14 and chronic myelogenous leukemia, BCR-ABL1 positive: Both M-MDSC (CD14+HLA-DR−) and G-MDSC (CD11b+CD33+CD14-HLA-DR−) were increased in the PB of CML patients compared to healthy controls and treatment with the tyrosine kinase inhibitor imatinib decreased the MDSC percentages to normal levels (25, 53).